10-Q: Vitro BioPharma Reports Q3 2026 Results Amidst Financial Challenges

Vitro BioPharma, Inc. filed its Form 10-Q for the quarter ended July 31, 2026, detailing significant net losses, a substantial increase in cash, and ongoing efforts to secure additional capital.

Summary

• Vitro BioPharma, Inc. reported a net loss of $8,543,737 for the three months ended July 31, 2026, and $11,203,930 for the nine months ended July 31, 2026.
• Total revenue for the three months ended July 31, 2026, decreased by 6% to $570,464 compared to the same period in 2025.
• Total revenue for the nine months ended July 31, 2026, decreased by 2% to $1,546,176 compared to the same period in 2025.
• The company's cash balance significantly increased from $604,183 as of October 31, 2025, to $5,737,675 as of July 31, 2026.
• Despite the increase in cash, the company has substantial accumulated deficits and net losses, raising substantial doubt about its ability to continue as a going concern.
• Significant losses on extinguishment of debt were recorded, primarily due to the conversion of various convertible notes payable into Series A-1 Preferred Stock.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant net losses, substantial debt, and ongoing concerns about the company's ability to continue as a going concern, despite some revenue growth in specific product lines.

Positives

• Significant increase in cash balance, from $604,183 to $5,737,675, providing more operational runway.
• InfiniVive product sales increased by 245% for the three months and 224% for the nine months ended July 31, 2026, indicating growing market acceptance.
• Research and development product sales saw a slight increase of 1% for the three months ended July 31, 2026.
• The company has a working capital surplus of approximately $2.7 million as of July 31, 2026.

Negatives

• Net loss of $8,543,737 for the three months and $11,203,930 for the nine months ended July 31, 2026.
• Total revenue decreased by 6% for the three-month period and 2% for the nine-month period compared to the prior year.
• Substantial accumulated deficit of $60,436,748 as of July 31, 2026.
• Significant losses on extinguishment of debt totaling $8,303,109 for the three months and $8,615,659 for the nine months ended July 31, 2026.
• Ongoing substantial doubt about the company's ability to continue as a going concern.
• Cost of goods sold increased significantly by 108% for the three months and 23% for the nine months ended July 31, 2026, outpacing revenue growth.
• Gross profit margin decreased from 89% to 75% for the three months and from 81% to 76% for the nine months ended July 31, 2026.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital through equity or debt financings and successfully implementing its business plan.
• Failure to raise sufficient capital could compel the company to curtail or cease operations.
• Clinical trials are subject to numerous risks and uncertainties, and their success is not guaranteed.
• The company faces significant competition in the biotechnology and regenerative medicine sectors.
• Regulatory approvals for product candidates are uncertain and subject to rigorous review.
• The company's ability to manage growth and attract/retain qualified personnel is critical.
• The company's financial statements do not include adjustments that might be necessary if it is unable to continue as a going concern.

Future Outlook

The company expects to continue reporting losses until it can improve operations or commercialize its product candidates. Future funding requirements are substantial and depend on clinical trial progress, regulatory approvals, and the ability to secure additional capital through equity or debt financings, collaborations, or licensing arrangements. The company anticipates commencing clinical trials in 2026, pending sufficient working capital.

Management Comments

• We expect that our SG&A expenses will increase in the future as we expect to increase our headcount to support increased research and development activities relating to our clinical programs.
• We expect our research and development expenses to increase significantly for the foreseeable future when we commence clinical trials and advance the pre-clinical and clinical development of our programs.
• We expect to continue reporting losses until such time, if ever, we can improve the operation of our subsidiaries and/or commercialize one or more of our product candidates and generate sales sufficient to offset our operating costs and expenses and interest expenses.
• Our ability to continue as a going concern is dependent upon our ability to raise additional funds through debt or equity financings and our ability to further implement our business plan and generate additional revenue.

Industry Context

StockSavvy.ai notes that Vitro BioPharma operates in the highly competitive and capital-intensive biotechnology sector, focusing on regenerative medicine and stem cell therapies. The company's reliance on external financing for clinical trials and operations is common in this industry, but the significant losses and going concern warnings highlight the inherent risks.

Comparison to Industry Standards

• Many early-stage biotechnology companies experience significant net losses and rely on external financing to fund research and development, which is consistent with Vitro BioPharma's situation.
• The substantial increase in cash, while positive for short-term liquidity, is often a precursor to significant capital expenditures for clinical trials or R&D, a common pattern in the sector.
• The company's focus on autoimmune diseases and inflammatory disorders aligns with major therapeutic areas of interest in the broader pharmaceutical and biotech industry.

Legal Proceedings

• No legal proceedings, government actions, administrative actions, investigations, or claims are currently pending or threatened against the company or its officers and directors.

Related Party Transactions

• Sales to Dr. Jack Zamora (former CEO and 29% stockholder) accounted for $0 in product sales for the three months and $0 for the nine months ended July 31, 2026.
• The spouse of the Chief Science Officer's entity leases office and lab space to the company, with no past due rent as of July 31, 2026.
• The company owes its CEO $22,610 in travel expense reimbursements and $970,000 in accrued, unpaid bonuses as of July 31, 2026.

Stakeholder Impact

• Shareholders face continued dilution risk from potential future equity financings and the ongoing net losses impacting the company's valuation.
• Creditors and noteholders are exposed to the company's going concern risk and the potential for further debt restructuring or conversion.
• Employees may face uncertainty due to the company's financial position and reliance on future capital raises.
• Customers and partners may be impacted by potential delays or curtailment of operations if funding is not secured.

Next Steps

• Commence clinical trials for AlloRx Stem Cell therapy in PTHS and Long COVID, pending receipt of sufficient working capital.
• Continue efforts to prepare AlloRx Stem Cell therapy and InfiniVive MD products for future clinical trials.
• Pursue additional capital through debt or equity financings, collaborations, licensing arrangements, or other sources.
• Expand headcount to support increased research and development activities.
• Seek regulatory approval for product candidates that successfully complete clinical development.
• Expand manufacturing capabilities and operational, financial, and management systems.

Key Dates

Recommendation

The company exhibits significant financial distress, characterized by substantial net losses, a large accumulated deficit, and a critical going concern warning. While there's a notable increase in cash, it's insufficient to overcome the fundamental financial challenges without substantial further capital raises, which are not guaranteed. The revenue decline and increased cost of goods sold further exacerbate the negative outlook, making it a sell recommendation.

Keywords

Biotechnology, Regenerative Medicine, Stem Cell Therapy, Clinical Trials, AlloRx, InfiniVive, Autoimmune Disorders, Long COVID